Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187063 · ClinicalTrials.gov registry record · NA
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
A NA study of Non-muscle Invasive Bladder Cancer (NMIBC), sponsored by Lahey Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT07187063 is a NA study of Non-muscle Invasive Bladder Cancer (NMIBC) that is actively recruiting participants, run by Lahey Clinic. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07187063, a NA study of Non-muscle Invasive Bladder Cancer (NMIBC), is actively recruiting participants, sponsored by Lahey Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST UroAmp Test (Convergent Genomics, Inc.)
Study Locations (1)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07187063
The ClinicalTrials.gov registry entry for NCT07187063 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer (NMIBC) appearing as the primary indexed condition, and to 1 intervention - of which UroAmp Test (Convergent Genomics, Inc.) is the first listed.
NCT07187063 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07187063 about?
NCT07187063 is a clinical study titled "Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer". The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
What is the current status of trial NCT07187063?
This trial is currently recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2025-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT07187063 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer (NMIBC).
What interventions are being tested in trial NCT07187063?
The interventions under investigation include: UroAmp Test (Convergent Genomics, Inc.) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07187063?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07187063 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer (NMIBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.